The Evolving Role of BTK Inhibitors in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Dr Haumschild, PharmD, MS, MBA leads a panel of experts identifying characteristics unique to MCL and addressing initial treatment strategies.

Drs Preetesh Jain and Michael Wang exchange insights regarding the current and prospective treatment options for patients with Mantle Cell Lymphoma.

Preetesh Jain, MBBS, MD, DM, PhD, offers perspective on unmet needs in treatment of patients with relapsed/refractory mantle cell lymphoma.

Ryan Haumschild, PharmD, MS, MBA, leads a discussion regarding the treatment of relapsed/refractory mantle cell lymphoma in the presence of comorbidities.

This panel of experts navigates the effects of BTK inhibitors, and their impact on trpatients with Mantle Cell Lymphoma.

Drs Haumschild, Jain, and Wang discuss clinical pearls regarding BTK inhibitors, including drug interactions.

Drs Jain and Wang discuss concerns regarding mutations in the treatment setting for patients with mantle cell lymphoma.

Experts navigate MCL drug interactions, including those between BTK inhibitors with common anticoagulants and antifungals.

Ryan Haumschild, PharmD, MS, MBA, enlightens the panel on the unique roles of pharmacists in treatment management for patients with mantle cell lymphoma.

The experts discuss their decision-making process in selecting treatment for patients with mantle cell lymphoma.

Key opinion leaders evaluate treatment options for MCL while emphasizing payer considerations.

Drs Haumschild, Jain, and Wang evaluate MCL therapies under investigation and the impact on the future of MCL treatment.

The experts provide their closing thoughts and discuss unmet needs in the treatment of patients with MCL.